Aptevo Therapeutics Inc. (APVO) Stock Analysis

Aptevo Therapeutics Inc. (APVO) Healthcare & Pipeline Overview

Aptevo Therapeutics Inc. is a clinical-stage biotechnology company specializing in immunotherapeutic candidates for cancer. Their lead candidate, APVO436, targets acute myelogenous leukemia and myelodysplastic syndrome. The company leverages its ADAPTIR platform to develop bispecific antibodies, positioning it within the competitive immuno-oncology landscape.

What Is the Investment Thesis for APVO?

Aptevo Therapeutics presents a high-risk, high-reward investment opportunity typical of clinical-stage biotechnology companies. The primary value driver is the successful development and commercialization of APVO436, currently in Phase 1b trials for AML and MDS. Positive clinical data from this trial could significantly increase the company's valuation. Further potential lies in the advancement of preclinical candidates like ALG.APV-527 and APVO603. However, the company faces significant risks, including clinical trial failures, regulatory hurdles, and the need for substantial additional funding. The company's market capitalization is approximately $10 million as of May 10, 2026, reflecting the inherent uncertainties of its pipeline. The collaboration with Alligator Bioscience AB provides some validation of Aptevo's technology and pipeline. Investment hinges on a positive outlook for APVO436's clinical development and the potential of its ADAPTIR platform.

Based on FMP financials and quantitative analysis

APVO Key Highlights

Aptevo's lead candidate, APVO436, is currently in Phase 1b clinical trials for acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS).

• The company's preclinical pipeline includes ALG.APV-527, a bispecific ADAPTIR candidate targeting 4-1BB (CD137) and 5T4, a tumor antigen expressed in various cancers.
• Aptevo has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527.
• Aptevo's ADAPTIR-FLEX platform is being utilized to develop APVO442, a bispecific candidate designed to enhance drug delivery to PSMA-positive tumors for prostate cancer treatment.
• Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.

Who Are APVO's Competitors?

APVO is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.

What Are APVO's Key Strengths?

Proprietary ADAPTIR platform for bispecific antibody development.

• Clinical-stage lead candidate APVO436 targeting AML and MDS.
• Collaboration with Alligator Bioscience AB.
• Experienced management team with expertise in immuno-oncology.

What Are APVO's Weaknesses?

Limited financial resources compared to larger biotechnology companies.

• Dependence on the success of a limited number of clinical candidates.
• High risk of clinical trial failures.
• Potential challenges in manufacturing and scaling up production of bispecific antibodies.

What Could Drive APVO Stock Higher?

APVO catalyst: APVO436 Phase 1b clinical trial data readout for AML and MDS (expected within 12-24 months).

• Initiation of clinical trials for ALG.APV-527 (expected within 2-3 years, pending preclinical data and regulatory approvals).
• Continued preclinical development of APVO603.
• Potential strategic partnerships with larger pharmaceutical companies.

What Are the Key Risks for APVO?

Financial-distress signal — its Altman Z-Score of -33.09 sits in the distress zone (elevated bankruptcy risk).

• Inconsistent delivery — missed Wall Street EPS estimates in 5 of the last 8 reported quarters.
• Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
• Clinical trial failures for APVO436 or other pipeline candidates.
• Regulatory hurdles and delays in clinical development.
• Limited financial resources and the need for additional funding.
• Competition from larger biotechnology and pharmaceutical companies.
• Changes in the healthcare landscape and reimbursement policies.

What Are the Growth Opportunities for APVO?

• APVO436 Clinical Advancement: The successful completion of Phase 1b clinical trials for APVO436 in AML and MDS represents a significant growth opportunity. Positive data could lead to further clinical development, potential partnerships, and eventual commercialization. The market for AML and MDS treatments is substantial, with a growing need for more effective therapies. Success in these indications could open doors to exploring APVO436 in other hematological malignancies. The timeline for this growth opportunity is dependent on clinical trial progress, with potential data readouts expected in the next 12-24 months.
• ALG.APV-527 Development: Advancing ALG.APV-527, the bispecific ADAPTIR candidate targeting 4-1BB (CD137) and 5T4, into clinical trials represents another key growth opportunity. 5T4 is a tumor antigen expressed in various cancers, making this candidate potentially applicable to a broad range of solid tumors. The collaboration with Alligator Bioscience AB provides additional resources and expertise for this program. The timeline for this growth opportunity is dependent on preclinical data and regulatory approvals, with potential clinical trial initiation in the next 2-3 years.
• APVO603 Preclinical Progress: Continued preclinical development of APVO603, the dual agonist bispecific antibody targeting 4-1BB and OX40, offers a longer-term growth opportunity. This candidate aims to stimulate two key immune co-stimulatory molecules, potentially enhancing anti-tumor immunity. Success in preclinical studies could lead to clinical trials and potential applications in various cancer types. The timeline for this growth opportunity is dependent on preclinical data and regulatory approvals, with potential clinical trial initiation in the next 3-4 years.
• ADAPTIR-FLEX Platform Expansion: Leveraging the ADAPTIR-FLEX platform to develop additional bispecific candidates represents a broader growth opportunity. This platform allows for the creation of modular bispecific antibodies with potential applications across a range of cancer types. Aptevo can explore new targets and indications, expanding its pipeline and diversifying its risk. The timeline for this growth opportunity is ongoing, with potential new candidate selection and development in the coming years.
• Strategic Partnerships: Forming strategic partnerships with larger pharmaceutical companies represents a significant growth opportunity. These partnerships could provide funding, expertise, and access to larger markets. Aptevo's ADAPTIR platform and pipeline of candidates could be attractive to companies seeking to expand their immuno-oncology portfolios. The timeline for this growth opportunity is uncertain, but potential partnership discussions could occur at any time based on clinical data and market interest.

What Are APVO's Competitive Advantages?

• Proprietary ADAPTIR platform for developing bispecific antibodies.
• Clinical-stage lead candidate APVO436 with potential for significant impact.
• Collaboration with Alligator Bioscience AB validates technology and provides resources.
• Pipeline of preclinical candidates targeting various cancer types.

What Does APVO Do?

Aptevo Therapeutics Inc., founded in 2016 and headquartered in Seattle, Washington, is a clinical-stage biotechnology company dedicated to developing novel immunotherapeutic candidates for various forms of cancer. The company's primary focus is on harnessing the power of the immune system to fight cancer through innovative bispecific antibody technology. Aptevo's lead clinical candidate, APVO436, is a bispecific T-cell engaging antibody currently in Phase 1b clinical trials for the treatment of acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS). This therapy aims to redirect T-cells to target and destroy cancer cells expressing specific antigens. In addition to APVO436, Aptevo has a pipeline of preclinical candidates, including ALG.APV-527, a bispecific ADAPTIR candidate targeting 4-1BB (CD137) and 5T4, a tumor antigen found in various cancers. APVO603, another preclinical asset, is a dual agonist bispecific antibody targeting 4-1BB and OX40. Aptevo is also developing APVO442, a bispecific candidate based on the ADAPTIR-FLEX platform, designed to enhance the delivery of drugs to PSMA-positive tumors for prostate cancer treatment. The company has a collaboration and option agreement with Alligator Bioscience AB to co-develop ALG.APV-527, expanding its research and development capabilities. Aptevo's ADAPTIR platform allows for the creation of modular bispecific antibodies with potential applications across a range of cancer types.

What Products and Services Does APVO Offer?

• Develop immunotherapeutic candidates for cancer treatment.
• Focus on bispecific antibody technology.
• Advance APVO436 through clinical trials for AML and MDS.
• Develop preclinical candidates like ALG.APV-527 and APVO603.
• Utilize the ADAPTIR platform to create novel bispecific antibodies.
• Collaborate with Alligator Bioscience AB on ALG.APV-527 development.
• Enhance drug delivery to PSMA-positive tumors for prostate cancer treatment with APVO442.

How Does APVO Make Money?

• Develop and out-license or sell novel immunotherapeutic candidates.
• Generate revenue through collaborations and partnerships.
• Advance clinical candidates through clinical trials to increase value.
• Focus on bispecific antibody technology for targeted cancer treatment.

What Industry Does APVO Operate In?

Aptevo Therapeutics operates within the competitive biotechnology industry, specifically focusing on immuno-oncology. This field is characterized by rapid innovation and intense competition, with numerous companies developing novel therapies to harness the immune system to fight cancer. The market for cancer immunotherapies is substantial and growing, driven by the increasing incidence of cancer and the limitations of traditional treatments like chemotherapy and radiation. Key trends include the development of bispecific antibodies, CAR-T cell therapies, and immune checkpoint inhibitors. Aptevo's ADAPTIR platform positions it to develop bispecific antibodies, potentially offering advantages in terms of efficacy and safety compared to existing therapies. The success of Aptevo depends on its ability to differentiate its candidates and navigate the complex regulatory landscape.

Who Are APVO's Key Customers?

• Potentially pharmaceutical companies through licensing agreements.
• Future patients who may benefit from their cancer therapies.
• Collaborators like Alligator Bioscience AB.

Over the past six months, Aptevo Therapeutics Inc. insiders filed 23 SEC Form 4 transactions — 12 sales and 11 purchases. On net that is roughly 561 shares disposed (about $2K), a signal worth weighing alongside the fundamentals.

Wall Street analysts project Aptevo Therapeutics Inc. revenue of about $7.5M for fiscal 2026, with EPS near $-17.04.

Aptevo Therapeutics Inc. has missed Wall Street's EPS estimate in 5 of its last 8 reported quarters — a mixed record worth weighing. Reported results have landed about 7248.8% below estimates on average.

Aptevo Therapeutics Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -33.09 places it in the distress zone, a signal of elevated financial risk.

APVO Revenue & Earnings Trend

In Jun 2026, APVO generated $0 in top-line revenue. The company recorded a net loss of $6.4M, with diluted EPS of $-5.31. Quarter-over-quarter revenue has been mixed, typical for a unknown company operating in Healthcare. Across the four most recent quarters, APVO averaged $-12.75 in diluted EPS.

Company Profile

Aptevo Therapeutics Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Seattle, US. The company is led by CEO Jeffrey G. Lamothe. APVO has traded publicly since 2016.

APVO Financials

APVO Latest News

APVO Analyst Consensus

APVO MoonshotScore

APVO Healthcare Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources